Lisbeth Enggaard
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.
Journal: Blood advances
Published: July 14, 2025
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: January 10, 2024
Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 21, 2023
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: May 10, 2023
Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
Journal: British journal of haematology
Published: October 03, 2022
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Journal: Frontiers in oncology
Published: August 19, 2022
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: February 05, 2022
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Journal: Blood
Published: August 10, 2020
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
Journal: European journal of haematology
Published: June 18, 2020
Last Updated: 09/26/2026